Safety testing of monoclonal antibodies in non-human primates: Case studies highlighting their impact on human risk assessment. Issue 1 (2nd January 2018)

• Record Type: Journal Article
• Authors: Brennan, Frank R.; Cavagnaro, Joy; McKeever, Kathleen; Ryan, Patricia C.; Schutten, Melissa M.; Vahle, John; Weinbauer, Gerhard F.; Marrer-Berger, Estelle; Black, Lauren E.
• Is Part Of: MAbs. Volume 10:Issue 1(2018)
• Page Start: 1
• Page End: 17
• Publication Date: 2018-01-02
• Subjects: Monoclonal antibody -- non-human primates -- safety testing -- risk assessment -- human translation -- case studies; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2017.1389364
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: Monoclonal antibodies (mAbs) are improving the quality of life for patients suffering from serious diseases due to their high specificity for their target and low potential for off-target toxicity. The toxicity of mAbs is primarily driven by their pharmacological activity, and therefore safety testing of these drugs prior to clinical testing is performed in species in which the mAb binds and engages the target to a similar extent to that anticipated in humans. For highly human-specific mAbs, this testing often requires the use of non-human primates (NHPs) as relevant species. It has been argued that the value of these NHP studies is limited because most of the adverse events can be predicted from the knowledge of the target, data from transgenic rodents or target-deficient humans, and other sources. However, many of the mAbs currently in development target novel pathways and may comprise novel scaffolds with multi-functional domains; hence, the pharmacological effects and potential safety risks are less predictable. Here, we present a total of 18 case studies, including some of these novel mAbs, with the aim of interrogating the value of NHP safety studies in human risk assessment. These studies have identified mAb candidate molecules and pharmacological pathways with severe safety risks, leading to candidate or target program termination, as well as highlighting that some pathways with theoretical safety concerns are amenable to safe modulation by mAbs. NHP studies have also informed the rational design of safer drug candidates suitable for human testing and informed human clinical trial design (route, dose and regimen, patient inclusion and exclusion criteria and safety monitoring), further protecting the safety of clinical trial participants.